Literature DB >> 7570736

Lipoprotein(a) serum concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease.

G Jürgens1, W C Taddei-Peters, P Költringer, W Petek, Q Chen, J Greilberger, P F Macomber, B T Butman, A G Stead, J H Ransom.   

Abstract

BACKGROUND AND
PURPOSE: Serum lipoprotein(a) [Lp(a)] levels are genetically determined and considered to be an independent risk factor for atherosclerosis. The aim of this study was to provide a complete analysis of Lp(a) serum levels, apolipoprotein(a) phenotypes, and other lipid parameters for different forms of severity of symptomatic ischemic cerebrovascular disorders as well as for different stages of carotid atherosclerosis.
METHODS: Lp(a) concentration, apolipoprotein(a) phenotype, triglyceride, low-density lipoprotein, high-density lipoprotein, and total cholesterol levels of blind-coded specimens as well as degree of carotid artery stenosis were assessed in a consecutive series of patients with ischemic cerebrovascular disease. We evaluated 265 male (34%) and female (66%) patients (mean age, 51 +/- 7.4 years) with transient ischemic attack (55.8%), prolonged reversible ischemic neurological deficits (28.3%), and cerebral infarction (15.9%) as well as 288 male (30%) and female (70%) control subjects (mean age, 51 +/- 7.1 years). All subjects were white.
RESULTS: Lp(a), total, and low-density lipoprotein cholesterol were statistically significantly elevated in all patients compared with control subjects. Lp(a) correlated with the severity of symptomatic cerebrovascular disease and the degree of carotid stenosis. Logistic regression analysis revealed Lp(a) as the best single marker for the presence of cerebrovascular disease (P < .001) followed by high-density lipoprotein cholesterol (P = .003) and triglycerides (P = .049). With a cutoff of 20 mg/dL of Lp(a), the odds ratio for a subject to have had ischemic stroke with elevated Lp(a) was 20.3 and 23.7 depending on the method of the Lp(a) estimation, whereas the odds ratio when the sonography score was > 0 was 15.4. The investigation of the distribution of the apo(a) phenotypes revealed that 16.73% of the control subjects had major isoforms < or = 580 kD molecular weight (B, F, S1, S2) versus 42.65% of the patients' group (P < .001). These isoforms were also present in 14.71% of all individuals with a sonography score of 0 but in 52.30% of all individuals with a sonography score > 0 (P < .001).
CONCLUSIONS: This case-control study shows that an elevated Lp(a) level is the primary factor associated with the presence of ischemic cerebrovascular disease and that the increased portion of the smaller-molecular-weight apo(a) isoforms in patients and individuals with a sonography score > 0 points toward an inherited predisposition for this disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7570736     DOI: 10.1161/01.str.26.10.1841

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  12 in total

Review 1.  Human cerebral microvessel endothelial cell culture as a model system to study the blood-brain interface in ischemic/hypoxic conditions.

Authors:  Zoltán Nagy; Mónika Vastag; Krasimir Kolev; Zoltán Bori; István Karáidi; Judit Skopál
Journal:  Cell Mol Neurobiol       Date:  2005-02       Impact factor: 5.046

2.  Relation of Apo(a) size to carotid atherosclerosis in an elderly multiethnic population.

Authors:  Furcy Paultre; Catherine H Tuck; Bernadette Boden-Albala; Douglas E Kargman; Elizabeth Todd; Jeffrey Jones; Myunghee C Paik; Ralph L Sacco; Lars Berglund
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-01       Impact factor: 8.311

3.  Evaluation of a new apolipoprotein(a) isoform-independent assay for serum Lipoprotein(a).

Authors:  T Dembinski; P Nixon; G Shen; D Mymin; P C Choy
Journal:  Mol Cell Biochem       Date:  2000-04       Impact factor: 3.396

Review 4.  Lipoprotein (a) and stroke.

Authors:  H J Milionis; A F Winder; D P Mikhailidis
Journal:  J Clin Pathol       Date:  2000-07       Impact factor: 3.411

5.  Lipoprotein (a) level, apolipoprotein (a) size, and risk of unexplained ischemic stroke in young and middle-aged adults.

Authors:  Azadeh Beheshtian; Sanyog G Shitole; Alan Z Segal; Dana Leifer; Russell P Tracy; Daniel J Rader; Richard B Devereux; Jorge R Kizer
Journal:  Atherosclerosis       Date:  2016-08-20       Impact factor: 5.162

6.  Analysis of cholesterol levels in lipoprotein(a) with anion-exchange chromatography.

Authors:  Yuji Hirowatari; Hiroshi Yoshida; Hideo Kurosawa; Yuko Shimura; Hidekatsu Yanai; Norio Tada
Journal:  J Lipid Res       Date:  2009-10-30       Impact factor: 5.922

7.  High Lipoprotein(a) Levels are Associated With Long-Term Adverse Outcomes in Acute Myocardial Infarction Patients in High Killip Classes.

Authors:  Jae Yeong Cho; Myung Ho Jeong; Youngkeun Ahn; Young Joon Hong; Hyung Wook Park; Nam Sik Yoon; Hyun Ju Yoon; Kye Hun Kim; Ju Han Kim; Jeong Gwan Cho; Jong Chun Park; Jung Chaee Kang
Journal:  Korean Circ J       Date:  2010-10-31       Impact factor: 3.243

Review 8.  The promise and potential pitfalls of serum biomarkers for ischemic stroke and transient ischemic attack.

Authors:  Matthew B Jensen; Marcus R Chacon; Justin A Sattin; Aitziber Aleu; Patrick D Lyden
Journal:  Neurologist       Date:  2008-07       Impact factor: 1.398

9.  Inhibition of neointima formation through DNA vaccination for apolipoprotein(a): a new therapeutic strategy for lipoprotein(a).

Authors:  Mariko Kyutoku; Hironori Nakagami; Hiroshi Koriyama; Futoshi Nakagami; Munehisa Shimamura; Hitomi Kurinami; Hideki Tomioka; Takashi Miyake; Tomohiro Katsuya; Ryuichi Morishita
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

10.  Lipoprotein(a) Is the Best Single Marker in Assessing Unstable Angina Pectoris.

Authors:  Vidosava B Djordjević; Vladan Cosić; Ivana Stojanović; Slavica Kundalić; Lilika Zvezdanović; Marina Deljanin-Ilić; Predrag Vlahović; Lidija Popović
Journal:  Cardiol Res Pract       Date:  2011-03-07       Impact factor: 1.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.